Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
2025-524722-17-00Phase 4Authorised
- Sponsor
- Region Skåne
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Region Skåne. Primary endpoint: Change in myocardial perfusion reserve from baseline to 2 years. Planned start Oct 2026; status: authorised.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2025-524722-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524722-17-00.